Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.
Lloyd MR, Chica-Parrado R, Weipert CM, Knepper TC, Podany EL, Napolitano F, Ye D, Lin CC, Uemoto Y, Liao J, Wegrzyn C, Walko CM, Ryan LY, Keenan JC, Medford AJ, Liu SA, Wulf GM, Clifton KK, Ma CX, Han HS, Zhang N, Ellisen LW, Bardia A, Arteaga CL, Hanker AB, Wander SA. Lloyd MR, et al. Among authors: arteaga cl. EBioMedicine. 2025 Jun 26;118:105828. doi: 10.1016/j.ebiom.2025.105828. Online ahead of print. EBioMedicine. 2025. PMID: 40578027 Free article.
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial.
Albanell J, Pozo AG, Arteaga CL, Bellet M, Rojo F, González A, Bellosillo B, Serra V, Gener P, Guerrero JA, Shimizu E, Mancino M, Rodríguez-Morató J, Mina L, Pérez-García JM, Cortés J, Llombart-Cussac A. Albanell J, et al. Among authors: arteaga cl. NPJ Breast Cancer. 2025 Jun 20;11(1):59. doi: 10.1038/s41523-025-00777-0. NPJ Breast Cancer. 2025. PMID: 40541946 Free PMC article.
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131).
Gouda MA, Janku F, Yuan Y, Drusbosky LM, Chen AP, Zheng X, Patel K, Hamilton SR, Routbort M, Tricoli JV, Williams PM, Iafrate AJ, Sklar J, Coffey B, Little RF, Arteaga CL, O'Dwyer PJ, Flaherty KT, Harris LN, Meric-Bernstam F. Gouda MA, et al. Among authors: arteaga cl. Clin Cancer Res. 2025 May 19. doi: 10.1158/1078-0432.CCR-24-3531. Online ahead of print. Clin Cancer Res. 2025. PMID: 40388547
Corrigendum to "Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations" [619 1 (2025) 217668 1-13].
Uemoto Y, A Lin CC, Wang B, Ye D, Fang YV, Bikorimana E, Napolitano F, Chica-Parrado MR, Li C, Mendiratta S, Chen C, Hanker AB, Arteaga CL. Uemoto Y, et al. Among authors: arteaga cl. Cancer Lett. 2025 Aug 28;626:217782. doi: 10.1016/j.canlet.2025.217782. Epub 2025 May 14. Cancer Lett. 2025. PMID: 40367673 Free article. No abstract available.
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H.
Gouda MA, Wei Z, Rodon J, Davies MA, Janku F, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Liu R, Bota DA, Swiecicki PL, Buchschacher GL, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Gouda MA, et al. Among authors: arteaga cl. JCO Precis Oncol. 2025 Feb;9:e2400451. doi: 10.1200/PO-24-00451. Epub 2025 Feb 6. JCO Precis Oncol. 2025. PMID: 39913886 Clinical Trial.
420 results